{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:41:51Z","timestamp":1790347311877,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T00:00:00Z","timestamp":1604880000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T00:00:00Z","timestamp":1604880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Bonn"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Little is known about the prevalence of a history of cancer and its impact on clinical outcome in mitral regurgitation (MR) patients undergoing transcatheter mitral valve repair (TMVR).<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>The purpose of this study is to investigate the prevalence of cancer, baseline inflammatory parameters, and clinical outcome in MR patients undergoing TMVR.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Consecutive patients undergoing a MitraClip procedure were enrolled, and the patients were stratified into two groups: cancer and non-cancer. Baseline complete blood counts (CBC) with differential hemograms were collected prior to the procedure to calculate the platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR). All-cause death within a one-year was examined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 82 out of 446 patients (18.4%) had a history of cancer. Cancer patients had a significantly higher baseline PLR [181.4 (121.1\u2013263.9) vs. 155.4 (109.4\u2013210.4);<jats:italic>P<\/jats:italic>\u2009=\u20090.012] and NLR [5.4 (3.5\u20138.3) vs. 4.0 (2.9\u20136.1);<jats:italic>P<\/jats:italic>\u2009=\u20090.002] than non-cancer patients. A Kaplan\u2013Meier analysis revealed that cancer patients had a significantly worse prognosis than non-cancer (estimated 1-year mortality, 20.2 vs. 9.2%; log-rank<jats:italic>P<\/jats:italic>\u2009=\u20090.009), and multivariable analyses of three models showed that cancer history was an independent factor for 1-year mortality. Patients who died during follow-up had a significantly higher baseline PLR [214.2 (124.2\u2013296.7) vs. 156.3 (110.2\u2013212.1);<jats:italic>P<\/jats:italic>\u2009=\u20090.007] and NLR [6.4 (4.2\u201312.5) vs. 4.0 (2.9\u20136.2);<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001] than survivors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In MitraClip patients, a history of cancer was associated with higher inflammatory parameters and worse prognosis compared to non-cancer patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Graphical Abstract<\/jats:title><jats:p>Central Illustration. Clinical outcomes and baseline PLR and NLR values accord-ing to one-year mortality. (Left) Patients who died within the follow-up period had a significantly higher baseline PLR (214.2 [124.2\u2013296.7] vs 156.3 [110.2\u2013212.1];<jats:italic>P<\/jats:italic>= 0.007) and NLR (6.4 [4.2\u201312.5] vs 4.0 [2.9\u20136.2];<jats:italic>P<\/jats:italic>&lt; 0.001) than patients who survived. PLR, platelet-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio (Right) A Kaplan-Meier analysis revealed that cancer patients had a significantly worse prognosis than non-cancer patients (estimated one-year mortality, 20.2 vs 9.2%; log-rank<jats:italic>P<\/jats:italic>= 0.009).<\/jats:p><\/jats:sec>","DOI":"10.1007\/s00392-020-01770-2","type":"journal-article","created":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T17:04:59Z","timestamp":1604941499000},"page":"440-450","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Impact of cancer history on clinical outcome in patients undergoing transcatheter edge-to-edge mitral repair"],"prefix":"10.1007","volume":"110","author":[{"given":"Noriaki","family":"Tabata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"\u00d6zt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Tsujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Nickenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Malte","family":"Sinning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,9]]},"reference":[{"key":"1770_CR1","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.jacc.2013.02.094","volume":"62","author":"F Maisano","year":"2013","unstructured":"Maisano F, Franzen O, Baldus S et al (2013) Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe. J Am Coll Cardiol 62:1052\u20131061","journal-title":"J Am Coll Cardiol"},{"key":"1770_CR2","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.jacc.2014.06.1166","volume":"64","author":"G Nickenig","year":"2014","unstructured":"Nickenig G, Estevez-Loureiro R et al (2014) Percutaneous mitral valve edge-to-edge repair: in-hospital results and 1-year follow-up of 628 patients of the 2011\u20132012 Pilot European Sentinel Registry. J Am Coll Cardiol 64:875\u2013884","journal-title":"J Am Coll Cardiol"},{"key":"1770_CR3","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMoa1805374","volume":"379","author":"JF Obadia","year":"2018","unstructured":"Obadia JF, Messika-Zeitoun D, Leurent G et al (2018) Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med 379:2297\u20132306","journal-title":"N Engl J Med"},{"key":"1770_CR4","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1806640","volume":"379","author":"GW Stone","year":"2018","unstructured":"Stone GW, Lindenfeld J, Abraham WT et al (2018) Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med 379:2307\u20132318","journal-title":"N Engl J Med"},{"key":"1770_CR5","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3322\/caac.21349","volume":"66","author":"KD Miller","year":"2016","unstructured":"Miller KD, Siegel RL, Lin CC et al (2016) Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 66:271\u2013289","journal-title":"CA Cancer J Clin"},{"key":"1770_CR6","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00392-018-1202-x","volume":"107","author":"LM Tilemann","year":"2018","unstructured":"Tilemann LM, Heckmann MB, Katus HA, Lehmann LH, M\u00fcller OJ (2018) Cardio-oncology: conflicting priorities of anticancer treatment and cardiovascular outcome. Clin Res Cardiol 107:271\u2013280","journal-title":"Clin Res Cardiol"},{"issue":"Suppl 6A","key":"1770_CR7","doi-asserted-by":"publisher","first-page":"9s","DOI":"10.1016\/j.amjmed.2004.02.006","volume":"116","author":"P Libby","year":"2004","unstructured":"Libby P, Ridker PM (2004) Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 116(Suppl 6A):9s\u201316s","journal-title":"Am J Med"},{"key":"1770_CR8","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature01322","volume":"420","author":"LM Coussens","year":"2002","unstructured":"Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860\u2013867","journal-title":"Nature"},{"key":"1770_CR9","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/ehjqcco\/qcx047","volume":"4","author":"N Tabata","year":"2018","unstructured":"Tabata N, Sueta D, Yamamoto E et al (2018) Outcome of current and history of cancer on the risk of cardiovascular events following percutaneous coronary intervention: a Kumamoto University Malignancy and Atherosclerosis (KUMA) study. Eur Heart J Qual Care Clin Outcomes 4:290\u2013300","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"1770_CR10","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13058-016-0794-1","volume":"19","author":"JL Ethier","year":"2017","unstructured":"Ethier JL, Desautels D, Templeton A, Shah PS, Amir E (2017) Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res 19:2","journal-title":"Breast Cancer Res"},{"key":"1770_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cca.2018.04.023","volume":"483","author":"B Li","year":"2018","unstructured":"Li B, Zhou P, Liu Y et al (2018) Platelet-to-lymphocyte ratio in advanced cancer: review and meta-analysis. Clin Chim Acta 483:48\u201356","journal-title":"Clin Chim Acta"},{"key":"1770_CR12","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.ijcard.2016.08.260","volume":"223","author":"JF Condado","year":"2016","unstructured":"Condado JF, Junpaparp P, Binongo JN et al (2016) Neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) can risk stratify patients in transcatheter aortic-valve replacement (TAVR). Int J Cardiol 223:444\u2013449","journal-title":"Int J Cardiol"},{"key":"1770_CR13","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1536\/ihj.18-196","volume":"60","author":"J Song","year":"2019","unstructured":"Song J, Zheng Q, Ma X et al (2019) Predictive roles of neutrophil-to-lymphocyte ratio and C-reactive protein in patients with calcific aortic valve disease. Int Heart J 60:345\u2013351","journal-title":"Int Heart J"},{"key":"1770_CR14","doi-asserted-by":"crossref","unstructured":"Tabata N, Al-Kassou B, Sugiura A, Kandt J, Shamekhi J, Stundl A, Zimmer S, Treede H, Ishii M, Tsujita K, Nickenig G, Werner N, Sinning JM (2020) Prognostic impact of cancer history in patients undergoing transcatheter aortic valve implantation. Clin Res Cardiol [Epub ahead of print]","DOI":"10.1007\/s00392-020-01615-y"},{"key":"1770_CR15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jcin.2018.10.026","volume":"12","author":"U Landes","year":"2019","unstructured":"Landes U, Iakobishvili Z, Vronsky D et al (2019) Transcatheter aortic valve replacement in oncology patients with severe aortic stenosis. JACC Cardiovasc Interv 12:78\u201386","journal-title":"JACC Cardiovasc Interv"},{"key":"1770_CR16","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1097\/HJH.0000000000001949","volume":"37","author":"N Tabata","year":"2019","unstructured":"Tabata N, Sueta D, Yamamoto E et al (2019) A retrospective study of arterial stiffness and subsequent clinical outcomes in cancer patients undergoing percutaneous coronary intervention. J Hypertens 37:754\u2013764","journal-title":"J Hypertens"},{"key":"1770_CR17","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1002\/ejhf.1491","volume":"21","author":"M Senni","year":"2019","unstructured":"Senni M, Adamo M, Metra M, Alfieri O, Vahanian A (2019) Treatment of functional mitral regurgitation in chronic heart failure: can we get a \u201cproof of concept\u201d from the MITRA-FR and COAPT trials? Eur J Heart Fail 21:852\u2013861","journal-title":"Eur J Heart Fail"},{"key":"1770_CR18","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/joim.12165","volume":"275","author":"C Kreatsoulas","year":"2014","unstructured":"Kreatsoulas C, Anand SS, Subramanian SV (2014) An emerging double burden of disease: the prevalence of individuals with cardiovascular disease and cancer. J Intern Med 275:494\u2013505","journal-title":"J Intern Med"},{"key":"1770_CR19","doi-asserted-by":"publisher","first-page":"e0178607","DOI":"10.1371\/journal.pone.0178607","volume":"12","author":"S Bando","year":"2017","unstructured":"Bando S, Soeki T, Matsuura T et al (2017) Plasma brain natriuretic peptide levels are elevated in patients with cancer. PLoS ONE 12:e0178607","journal-title":"PLoS ONE"},{"key":"1770_CR20","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","volume":"357","author":"F Balkwill","year":"2001","unstructured":"Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539\u2013545","journal-title":"Lancet"},{"key":"1770_CR21","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1245\/s10434-015-4869-5","volume":"23","author":"H Yodying","year":"2016","unstructured":"Yodying H, Matsuda A, Miyashita M et al (2016) Prognostic significance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in oncologic outcomes of esophageal cancer: a systematic review and meta-analysis. Ann Surg Oncol 23:646\u2013654","journal-title":"Ann Surg Oncol"},{"key":"1770_CR22","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1159\/000485396","volume":"44","author":"J Zheng","year":"2017","unstructured":"Zheng J, Cai J, Li H et al (2017) Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio as prognostic predictors for hepatocellular carcinoma patients with various treatments: a meta-analysis and systematic review. Cell Physiol Biochem 44:967\u2013981","journal-title":"Cell Physiol Biochem"},{"key":"1770_CR23","doi-asserted-by":"publisher","first-page":"37200","DOI":"10.18632\/oncotarget.16553","volume":"8","author":"M Deng","year":"2017","unstructured":"Deng M, Ma X, Liang X, Zhu C, Wang M (2017) Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer? Oncotarget 8:37200\u201337207","journal-title":"Oncotarget"},{"key":"1770_CR24","first-page":"1029","volume":"146","author":"HF Dvorak","year":"1995","unstructured":"Dvorak HF, Brown LF, Detmar M, Dvorak AM (1995) Vascular permeability factor\/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146:1029\u20131039","journal-title":"Am J Pathol"},{"key":"1770_CR25","doi-asserted-by":"publisher","first-page":"4895","DOI":"10.1158\/1078-0432.CCR-03-0760","volume":"10","author":"JE De Larco","year":"2004","unstructured":"De Larco JE, Wuertz BR, Furcht LT (2004) The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clin Cancer Res 10:4895\u20134900","journal-title":"Clin Cancer Res"},{"key":"1770_CR26","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1634\/theoncologist.2-5-280","volume":"2","author":"JE Niederhuber","year":"1997","unstructured":"Niederhuber JE (1997) Cancer vaccines: the molecular basis for T cell killing of tumor cells. Oncologist 2:280\u2013283","journal-title":"Oncologist"},{"key":"1770_CR27","doi-asserted-by":"crossref","first-page":"230","DOI":"10.4049\/jimmunol.134.1.230","volume":"134","author":"HT Petrie","year":"1985","unstructured":"Petrie HT, Klassen LW, Kay HD (1985) Inhibition of human cytotoxic T lymphocyte activity in vitro by autologous peripheral blood granulocytes. J Immunol 134:230\u2013234","journal-title":"J Immunol"},{"key":"1770_CR28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.atherosclerosis.2017.02.003","volume":"259","author":"Y Li","year":"2017","unstructured":"Li Y, Zhong X, Cheng G, Zhao C, Zhang L, Hong Y, Wan Q, He R, Wang Z (2017) Hs-CRP and all-cause, cardiovascular, and cancer mortality risk: a meta-analysis. Atherosclerosis 259:75\u201382","journal-title":"Atherosclerosis"},{"key":"1770_CR29","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1515\/enr-2017-0013","volume":"51","author":"S Ozmen","year":"2017","unstructured":"Ozmen S, Timur O, Calik I, Altinkaynak K, Simsek E, Gozcu H, Arslan A, Carlioglu A (2017) Neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) may be superior to C-reactive protein (CRP) for predicting the occurrence of differentiated thyroid cancer. Endocr Regul 51:131\u2013136","journal-title":"Endocr Regul"},{"key":"1770_CR30","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s10654-018-0472-y","volume":"34","author":"J Fest","year":"2019","unstructured":"Fest J, Ruiter TR, Koerkamp BG, Rizopoulos D, Ikram MA, van Eijck CHJ, Stricker BH (2019) The neutrophil-to-lymphocyte ratio is associated with mortality in the general population: the Rotterdam study. Eur J Epidemiol 34:463\u2013470","journal-title":"Eur J Epidemiol"},{"key":"1770_CR31","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s00392-019-01516-9","volume":"109","author":"AI K\u00e4lsch","year":"2020","unstructured":"K\u00e4lsch AI, Scharnagl H, Kleber ME, Windpassinger C, Sattler W, Leipe J, Kr\u00e4mer BK, M\u00e4rz W, Malle E (2020) Long- and short-term association of low-grade systemic inflammation with cardiovascular mortality in the LURIC study. Clin Res Cardiol 109:358\u2013373","journal-title":"Clin Res Cardiol"},{"key":"1770_CR32","doi-asserted-by":"publisher","first-page":"682","DOI":"10.2174\/1573406410666140318113325","volume":"10","author":"G Bouras","year":"2014","unstructured":"Bouras G, Giannopoulos G, Hatzis G, Alexopoulos D, Leventopoulos G, Deftereos S (2014) Inflammation and chronic heart failure: from biomarkers to novel anti-inflammatory therapeutic strategies. Med Chem 10:682\u2013699","journal-title":"Med Chem"},{"key":"1770_CR33","first-page":"606","volume":"105","author":"E Durmus","year":"2015","unstructured":"Durmus E, Kivrak T, Gerin F, Sunbul M, Sari I, Erdogan O (2015) Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are predictors of heart failure. Arq Bras Cardiol 105:606\u2013613","journal-title":"Arq Bras Cardiol"},{"key":"1770_CR34","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1007\/s00392-019-01417-x","volume":"108","author":"HJ Yoon","year":"2019","unstructured":"Yoon HJ, Kim KH, Kim HY, Park H, Cho JY, Hong YJ, Park HW, Kim JH, Ahn Y, Jeong MH, Cho JG, Park JC (2019) Impacts of non-recovery of trastuzumab-induced cardiomyopathy on clinical outcomes in patients with breast cancer. Clin Res Cardiol 108:892\u2013900","journal-title":"Clin Res Cardiol"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-020-01770-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00392-020-01770-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-020-01770-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T22:03:53Z","timestamp":1697061833000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00392-020-01770-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,9]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["1770"],"URL":"https:\/\/doi.org\/10.1007\/s00392-020-01770-2","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,9]]},"assertion":[{"value":"28 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Drs. Sinning and Nickenig have received speaker honoraria and research grants from Abbott, Abiomed, Medtronic, Boston Scientific, and Edwards Lifesciences. Dr. Tsujita has received grants from Abbott Vascular Japan, Medtronic Japan, and Boston Scientific Japan. The other authors report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}